Company intelligence / Profile preview

Anima Research

Bernardsville, New Jersey, United Statesanimaresearch.com ↗

Ownership: Private
Development stage: Commercial

Overview

Anima Biotech has developed a proprietary AI-driven platform for discovering small molecule drugs that selectively control the translation of specific proteins by targeting their mRNAs. Their approach enables drugging previously undruggable targets and has led to a broad pipeline in fibrosis, oncology, neuroscience, and pain. The company has established major partnerships with AbbVie, Takeda, and Eli Lilly for both internal and partnered programs. Most internal assets are preclinical; partnered assets' stages depend on collaboration progress.

Therapeutic areas: PulmonologyOncologyNeurology
Modalities: Small moleculeRNA therapy
Industry: Biotech

Partnerships

AbbVie ($42M upfront + milestones up to $540M+)Takeda Pharmaceuticals ($120M upfront/milestones; total deal value up to $2B+)Eli Lilly

Beyond the preview

Go deeper on Anima Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anima Research.

Explore the full profile